NCT01946906View on ClinicalTrials.gov

The Rifaximin Study in CVID

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Common Variable Immunodeficiency (CVID)
Interventions
DRUG

Rifaximin

Trial Locations (1)

Unknown

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT01946906 - The Rifaximin Study in CVID | Biotech Hunter | Biotech Hunter